Stock Market Reviews

KLTO (Klotho Neurosciences, Inc.) News

Get the latest news, insights, and market updates on KLTO (Klotho Neurosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
  Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery.
  Jul 22, 2025 - $KLTO
• Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
  Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).
  Jul 16, 2025 - $KLTO
• Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
  Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS.
  Jul 10, 2025 - $KLTO
• Klotho Neurosciences Begins Manufacture, Prep Work Ahead of Clinical Trials of Potential Sclerosis Therapy
  Klotho Neurosciences (KLTO) said Monday that it is beginning manufacturing and development work in p
  Jun 30, 2025 - $KLTO
• Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
  Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS).
  Jun 30, 2025 - $KLTO
• Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
  Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer's Disease (AD) and Parkinson's Disease (PD), has announced that it is partnering with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of the Okinawa Research Center for Longevity Science (ORCLS), as part of its research program on Okinawa, Japan, where a comparatively high number peo
  Jun 24, 2025 - $KLTO
• KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
  Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho," "KLTO," or the "Company") today announced that on June 13, 2025, it entered into a Termination and Release Agreement with SkyBell Technologies, Inc. ("SkyBell"), formally ending the Share Exchange Agreement previously executed on March 26, 2025.
  Jun 18, 2025 - $KLTO
• KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT
  Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq's stockholders' equity requirement requirements outlined in its Nasdaq compliance plan.
  Jun 16, 2025 - $KLTO
• KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")
  Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span.
  Jun 9, 2025 - $KLTO
• Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
  Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union SquareNEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. T
  Jan 8, 2025 - $KLTO